| scholarly article | Q13442814 |
| P50 | author | Roberto Berni Canani | Q43264118 |
| Gianluca Terrin | Q47503729 | ||
| Claudio Romano | Q51191456 | ||
| Lorenzo Morelli | Q54065164 | ||
| Alfredo Guarino | Q61314552 | ||
| P2093 | author name string | Francesco Manguso | |
| Pia Cirillo | |||
| Annalisa Passariello | |||
| Basilio Malamisura | |||
| Paola Roggero | |||
| Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pneumonia | Q12192 |
| gastroenteritis | Q156103 | ||
| P304 | page(s) | e817-20 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | Pediatrics | Q7159238 |
| P1476 | title | Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. | |
| P478 | volume | 117 |
| Q35235645 | 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. |
| Q28259245 | A review of stress-related mucosal disease |
| Q47911674 | ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW. |
| Q33338273 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole |
| Q38916823 | Adult and paediatric GERD: diagnosis, phenotypes and avoidance of excess treatments. |
| Q37807790 | Advances in the surgical management of gastroesophageal reflux |
| Q34167899 | Adverse effects of long-term proton pump inhibitor therapy |
| Q28082238 | Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review |
| Q35178642 | Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. |
| Q34625515 | Anti-acid medication as a risk factor for food allergy |
| Q46423325 | Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children |
| Q57476362 | Association of Proton Pump Inhibitors With Hospitalization Risk in Children With Oropharyngeal Dysphagia |
| Q37402038 | Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth. |
| Q35001102 | Clinical practice guideline: hoarseness (dysphonia). |
| Q37561598 | Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients |
| Q38202595 | Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease |
| Q29028573 | Consensus Statement for Standard of Care in Spinal Muscular Atrophy |
| Q37892887 | Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review |
| Q57480255 | Does Obesity Increase Respiratory Tract Infections in Patients with Asthma? |
| Q28555174 | Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach |
| Q40195832 | Duodenal tube feeding: an alternative approach for effectively promoting weight gain in children with gastroesophageal reflux and congenital heart disease |
| Q37481108 | Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications |
| Q37378692 | Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients |
| Q93384440 | Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore |
| Q38109860 | Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease |
| Q38153767 | Esophagitis in children: an update on current pharmacotherapy |
| Q35683435 | Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies |
| Q88045092 | GERD: body position affects infant GER but not symptoms |
| Q41573395 | Gastro-Esophageal Reflux in Children |
| Q26860927 | Gastro-esophageal reflux disease in healthy older children and adolescents |
| Q38238554 | Gastro-esophageal reflux: spitting and possetting in a neonate |
| Q51002982 | Gastroesophageal Reflux Disease. |
| Q37960158 | Gastroesophageal reflux disease in children and adolescents: when and how to treat |
| Q93148090 | Gastroesophageal reflux in children: an updated review |
| Q33561975 | Gastrointestinal motility disorders in children |
| Q41915405 | Higher rate of bronchoalveolar lavage culture positivity in children with nonacid reflux and respiratory disorders |
| Q50046505 | Infant Reflux in the Primary Care Setting: A Brief Educational Intervention and Management Changes |
| Q58805899 | Infantile colic |
| Q33917155 | Infection-related asthma |
| Q38041609 | Inhibitors of gastric acid secretion drugs increase neonatal morbidity and mortality. |
| Q37055804 | Integrative Treatment of Reflux and Functional Dyspepsia in Children |
| Q84148652 | Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule |
| Q53087453 | Italian survey on general pediatricians' approach to children with gastroesophageal reflux symptoms. |
| Q96129229 | Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial |
| Q30300235 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype |
| Q34127482 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial |
| Q36797405 | Laryngopharyngeal reflux and chronic sinusitis |
| Q36901663 | Long-term proton pump inhibitor use in children: a retrospective review of safety |
| Q37808356 | Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole |
| Q49501068 | Management of gastroesophageal reflux disease in pediatric patients: a literature review |
| Q59154127 | Medical intervention in parent-reported infant gastro-oesophageal reflux: A population-based study |
| Q37047798 | Neonatal Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Treatment at United States Children's Hospitals |
| Q33324409 | Nitric oxide antagonizes the acid tolerance response that protects Salmonella against innate gastric defenses |
| Q57807726 | Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial |
| Q43854731 | Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials |
| Q37271717 | Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. |
| Q90419632 | Pediatric Intestinal Failure Review |
| Q64082419 | Pediatric Intestinal Failure: A Review of the Scope of Disease and a Regional Model of a Multidisciplinary Care Team |
| Q33584890 | Pediatric specialists' beliefs about gastroesophageal reflux disease in premature infants |
| Q33409626 | Perils and pitfalls of long-term effects of proton pump inhibitors |
| Q41706384 | Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs |
| Q38123481 | Pharmacological therapy of gastroesophageal reflux in preterm infants. |
| Q50324881 | Pharmacological treatment of children with gastro-oesophageal reflux |
| Q37215474 | Potential adverse effects of proton pump inhibitors |
| Q35865246 | Potential protective effects of Clostridium butyricum on experimental gastric ulcers in mice |
| Q46894129 | Proton Pump Inhibitor Use Is Associated With an Increased Frequency of Hospitalization in Patients With Cystic Fibrosis. |
| Q34589801 | Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009 |
| Q24655315 | Proton pump inhibitors and gastritis |
| Q42264809 | Proton pump inhibitors for irritable infants |
| Q39261292 | Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions. |
| Q39238716 | Questionnaire-based survey in a developing country showing noncompliance with paediatric gastro-oesophageal reflux practice guidelines |
| Q37831951 | Review article: methods of measuring gastric acid secretion |
| Q34092977 | Risk of fracture and pneumonia from acid suppressive drugs |
| Q38460850 | Role of acid-suppressing medications during a sustained outbreak of Salmonella enteritidis infection in a long-term care facility |
| Q38442609 | Safety of medication options for treating pediatric esophagitis |
| Q42759475 | Safety profile of six months lansoprozole treatment in children |
| Q90267117 | Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review |
| Q37215537 | Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children |
| Q88988177 | The Edematous and Erythematous Airway Does Not Denote Pathologic Gastroesophageal Reflux |
| Q91646605 | The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid |
| Q30399991 | The sensitivity of acoustic cough recording relative to intraesophageal pressure recording and patient report during reflux testing |
| Q34686906 | The systems biology of infection in animal models bears fruit |
| Q37731243 | Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis |
| Q81356779 | Treatment options in pediatric GERD |
| Q42540006 | Update on endoscopic diagnosis, management and surveillance strategies of esophageal diseases |
| Q39035540 | Use of Gastroesophageal Reflux Medications in Premature Infants After NICU Discharge |
| Q22241389 | Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis |
| Q33742768 | Use of ranitidine is associated with infections in newborns hospitalized in a neonatal intensive care unit: a cohort study |
| Q50533708 | Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: an observational cohort study. |
| Q28072141 | Widespread use of gastric acid inhibitors in infants: Are they needed? Are they safe? |
| Q50234487 | Inhibiteurs de la pompe à protons pour les nourrissons irritables. |
Search more.